Abstract
Importance Previous studies identify putative genes associated with diabetic retinopathy only focusing on specific clinical stage, thus resulting genes are not necessarily reflective of disease progression.
Objective To identify genes associated with the severity level of diabetic retinopathy using likelihood-ration test (LRT) and ordinal logistic regression (OLR) model, as well as to profile immune and retinal cell landscape in progressive diabetic retinopathy using a machine learning deconvolution approach.
Design, Setting, and Participants This study used published transcriptomic dataset (GSE160306) from macular regions of donors with different degrees of diabetic retinopathy (10 healthy controls, 10 cases of diabetes, 9 cases of nonproliferative diabetic retinopathy and 10 cases of proliferative diabetic retinopathy or combined with diabetic macular edema). Transcriptomic dataset was released on April 19, 2021; data were analyzed on 28th March 2022.
Main Outcomes and Measures Identification of severity-associated genes with LRT and OLR model and proportional changes of immune and retinal cells in progressive diabetic retinopathy.
Results By controlling for gender and age using LRT and OLR, 50 genes were identified to be significantly increased in expression with the severity of diabetic retinopathy. Functional enrichment analyses suggested these severity-associated genes are related to inflammation and immune responses. CCND1 and FCGR2B are further identified as key regulators to interact with many other severity-associated genes and are crucial to inflammation. Deconvolution analyses demonstrated that the proportions of memory B cells, M2 macrophages and Müller glia were significantly increased with the progression of diabetic retinopathy.
Conclusions and Relevance These findings demonstrate the deep analyses of transcriptomic data can advance our understanding of progressive ocular diseases, such as DR, by applying LRT and OLR model as well as bulk gene expression deconvolution.
Question Do genes change in expression or immune cells and retinal cells change in proportions in the human retina with the severity of diabetic retinopathy?
Findings In this in-depth retinal transcriptomic analysis of 39 participants, consisting of 10 heathy controls, 29 cases of diabetic retinopathy at different clinical stages, severity-associated genes were identified, and the estimated proportions of immune cell and retinal cells were profiled, respectively.
Meaning These findings demonstrate that a group of genes are significantly increased in expression, and the proportions of memory B cells, M2 macrophages and Müller glia were significantly increased with the severity of diabetic retinopathy.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by grants from the National Health and Medical Research Council of Australia (GNT1185600). The Centre for Eye Research Australia receives Operational Infrastructure Support from the Victorian Government.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
RNA-Seq raw counts were obtained from Gene Expression Omnibus (GSE160306, accessed on 28th March 2022).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Analysis scripts will be made available upon request. RNA-Seq raw counts were obtained from Gene Expression Omnibus (GSE160306, accessed on 28th March 2022).
